Pay in 4 interest-free payments of $6.56 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis
CJC-1295 increases GH release by binding to receptors on the surface of cells in the pituitary gland
Who Should Consider It Anyone with elevated toxin burden (heavy metal exposure, mycotoxin illness, chemical sensitivities) requiring enhanced Phase II detox capacity Individuals undergoing structured detoxification protocols where adequate GSH conjugation capacity is critical Those with chronic illness, autoimmune conditions, or persistent inflammation associated with oxidative stress and GSH depletion Biohackers focused on mitochondrial health, longevity, and cellular redox optimisation High-performance athletes experiencing high oxidative stress from training load Anyone with a history of significant pharmaceutical exposure (statins, acetaminophen, and many other drugs deplete hepatic GSH) Ready to upgrade your antioxidant foundation
Lau, D.C.W., et al
US$ 27.45
US$ 27.92
US$ 29.77
US$ 22.85
US$ 23.58
US$ 27.28
